Open Access
ARTICLE
Glutamine transporters as effective targets in digestive system malignant tumor treatment
FEI CHU1, KAI TONG1, XIANG GU1, MEI BAO1, YANFEN CHEN1, BIN WANG2, YANHUA SHAO1, LING WEI1,*
1 School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, 510006, China
2 Department of Pharmacy, Tianjin Medical University General Hospital, Tianjin, 300070, China
Oncology Research https://doi.org/10.32604/or.2024.048287
Received 03 December 2023; Accepted 07 April 2024; Published online 08 May 2024
Abstract
Glutamine is one of the most abundant non-essential amino acids in human plasma and plays a crucial role in
many biological processes of the human body. Tumor cells take up a large amount of glutamine to meet their rapid
proliferation requirements, which is supported by the upregulation of glutamine transporters. Targeted inhibition of
glutamine transporters effectively inhibits cell growth and proliferation in tumors. Among all cancers, digestive system
malignant tumors (DSMTs) have the highest incidence and mortality rates, and the current therapeutic strategies for
DSMTs are mainly surgical resection and chemotherapy. Due to the relatively low survival rate and severe side effects
associated with DSMTs treatment, new treatment strategies are urgently required. This article summarizes the
glutamine transporters involved in DSMTs and describes their role in DSMTs. Additionally, glutamine transportertarget drugs are discussed, providing theoretical guidance for the further development of drugs DSMTs treatment.
Keywords
Glutamine transporter, Targeted therapy, Inhibitors, Cancer
Login
Register
Submit a Paper
Propose a Special lssue
Download PDF
Downloads
Citation Tools
